Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

TCT 2021 | SIERRA trial updates: apamistamab in AML

Tania Jain • 12 Feb 2021
TCT 2021
Acute Myeloid Leukemia Leukemia Apamistamab
SIERRA

Tania Jain, MBBS, Johns Hopkins University, Baltimore, MD, outlines key updates in the treatment of leukemia as presented at this year’s Transplantation & Cellular Therapy (TCT) 2021 meeting including two abstracts evaluating the use of targeted radioimmunotherapy with an anti-CD45 antibody, apamistamab (Iomab-B) in patients with acute myeloid leukemia. This interview took place during the Transplantation & Cellular Therapy (TCT) 2021 Meetings.

Explore the AML Channel banner with headshots of Naval Daver, Eunice Wang, and Thomas Cluzeau

More from Tania Jain

Changes in the duration of the monitoring period following CAR T-cell infusion
1:35
Changes in the duration of the monitoring period following CAR T-cell infusion
Tania Jain • 23 Aug 2025
Strategies for mitigating infection risk in patients treated with CAR T-cell therapy
3:19
Strategies for mitigating infection risk in patients treated with CAR T-cell therapy
Tania Jain • 23 Aug 2025
Immunotherapy in MPNs: antibodies, CAR-T, and more
2:31
Immunotherapy in MPNs: antibodies, CAR-T, and more
Tania Jain • 23 Aug 2025
Cellular therapy modalities being explored for the prevention of post-transplant relapse
3:15
Cellular therapy modalities being explored for the prevention of post-transplant relapse
Tania Jain • 24 Aug 2024

Related Videos

Unmet needs in CLL genomics: heterogeneity and clinical impact
1:11
Unmet needs in CLL genomics: heterogeneity and clinical impact
Elias Campo • 16 Oct 2026
Insights into key topics most likely to impact day-to-day CLL management
1:40
Insights into key topics most likely to impact day-to-day CLL management
Alessandra Ferrajoli • 16 Oct 2026
Translating current CLL evidence into national guidelines: which gaps remain?
3:33
Translating current CLL evidence into national guidelines: which gaps remain?
Mary Ann Anderson • 16 Oct 2026
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
2:40
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
Philip Thompson • 22 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals